KR20160137945A - 신경퇴행성 질환의 치료에 유용한 위타놀라이드 - Google Patents

신경퇴행성 질환의 치료에 유용한 위타놀라이드 Download PDF

Info

Publication number
KR20160137945A
KR20160137945A KR1020167015115A KR20167015115A KR20160137945A KR 20160137945 A KR20160137945 A KR 20160137945A KR 1020167015115 A KR1020167015115 A KR 1020167015115A KR 20167015115 A KR20167015115 A KR 20167015115A KR 20160137945 A KR20160137945 A KR 20160137945A
Authority
KR
South Korea
Prior art keywords
patient
hydrogen
compound
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167015115A
Other languages
English (en)
Korean (ko)
Inventor
안토니 에이 쇼
장-피에르 줄리안
아그네스 에이치 찬
Original Assignee
임스타 테라퓨틱스 인크.
유니버시티 라발
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 임스타 테라퓨틱스 인크., 유니버시티 라발 filed Critical 임스타 테라퓨틱스 인크.
Publication of KR20160137945A publication Critical patent/KR20160137945A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020167015115A 2013-11-25 2014-11-25 신경퇴행성 질환의 치료에 유용한 위타놀라이드 Ceased KR20160137945A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361908455P 2013-11-25 2013-11-25
US61/908,455 2013-11-25
PCT/US2014/067436 WO2015077780A1 (en) 2013-11-25 2014-11-25 Withanolides useful for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
KR20160137945A true KR20160137945A (ko) 2016-12-02

Family

ID=52023694

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167015115A Ceased KR20160137945A (ko) 2013-11-25 2014-11-25 신경퇴행성 질환의 치료에 유용한 위타놀라이드

Country Status (14)

Country Link
US (1) US10351590B2 (https=)
EP (1) EP3074414B1 (https=)
JP (1) JP6517833B2 (https=)
KR (1) KR20160137945A (https=)
CN (1) CN105940010B (https=)
AU (1) AU2014352629B2 (https=)
BR (1) BR112016012002A2 (https=)
CA (1) CA2931064C (https=)
ES (1) ES2728870T3 (https=)
MX (1) MX364528B (https=)
PL (1) PL3074414T3 (https=)
TR (1) TR201905218T4 (https=)
WO (1) WO2015077780A1 (https=)
ZA (1) ZA201603117B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210079035A1 (en) * 2017-12-11 2021-03-18 Ethnodyne Compounds for treating neurodegenerative disorders
EP3723859B1 (en) * 2017-12-11 2023-08-30 Ethnodyne Compounds for treating neurodegenerative disorders
WO2019116069A1 (en) * 2017-12-11 2019-06-20 Ethnodyne Compounds for treating neurodegenerative disorders
CN111377994A (zh) * 2018-12-28 2020-07-07 南开大学 七种来源于灯笼果的醉茄内酯类化合物及其制备方法和用途
CN116063373B (zh) * 2023-02-14 2025-04-15 广西医科大学 天然产物27-Deoxywithaferin A的制备方法
TW202521103A (zh) * 2023-10-03 2025-06-01 美商恩維達醫療公司 醉茄素a（withaferin a）類似物及使用彼之治療方法
CN117924401A (zh) * 2024-01-22 2024-04-26 黑龙江中医药大学 一种具有神经炎症抑制活性的化合物及其提取方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010030395A2 (en) 2008-09-15 2010-03-18 Whitehead Institute For Biomedical Research Withaferin a analogs and uses thereof
WO2010053655A2 (en) * 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
WO2012106393A2 (en) * 2011-02-01 2012-08-09 University Of Kansas Withanolide isolated from physalis longifolia and analogs and methods of use thereof
CA2839777C (en) * 2011-06-22 2021-10-19 Universite Laval Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease

Also Published As

Publication number Publication date
US10351590B2 (en) 2019-07-16
ZA201603117B (en) 2020-05-27
CN105940010A (zh) 2016-09-14
WO2015077780A1 (en) 2015-05-28
US20170022247A1 (en) 2017-01-26
CN105940010B (zh) 2018-03-30
PL3074414T3 (pl) 2019-12-31
JP6517833B2 (ja) 2019-05-22
BR112016012002A2 (pt) 2017-09-19
TR201905218T4 (tr) 2019-05-21
AU2014352629A1 (en) 2016-05-26
MX364528B (es) 2019-04-30
MX2016006544A (es) 2016-12-12
AU2014352629B2 (en) 2019-03-28
EP3074414A1 (en) 2016-10-05
EP3074414B1 (en) 2019-01-09
JP2016537432A (ja) 2016-12-01
ES2728870T3 (es) 2019-10-29
CA2931064A1 (en) 2015-05-28
CA2931064C (en) 2022-10-18

Similar Documents

Publication Publication Date Title
KR20160137945A (ko) 신경퇴행성 질환의 치료에 유용한 위타놀라이드
CN106103452B (zh) 皮质抑素类似物及其合成和用途
CH631696A5 (de) Verfahren zur herstellung von olefinischen derivaten von aminosaeuren.
US20070032456A1 (en) Modulation of cell death
EP1317426B1 (de) Beta-thio-aminosäuren
Madsen et al. NMDA receptor agonists derived from ibotenic acid. Preparation, neuroexcitation and neurotoxicity
RU2672569C2 (ru) Новое производное оксима хромона и его использование в качестве аллостерического модулятора метаботропных рецепторов глутамата
US11472832B2 (en) Withanolides useful for the treatment of neurodegenerative diseases
JP7295145B2 (ja) 神経変性疾患を治療するための医薬及びその使用
DE69121000T2 (de) Alpha-Mannosidase- und fucosidase-Hemmer
JP7382944B2 (ja) 神経変性疾患を予防・治療するための新規な化合物及びその応用
WO2024056865A1 (en) Compounds for the treatment of neuromuscular disorders
JP4824693B2 (ja) ピペリジン誘導体、それを含有する薬剤組成物、及び調製方法
DD298786A5 (de) Thiophene
EP0460358B1 (en) Agent for treating disorders from cerebral neuro-degeneration
RU2799454C2 (ru) Терапевтический препарат для лечения нейродегенеративных заболеваний и его применение
JP2024507798A (ja) 抗コリンエステラーゼ活性を有する６－メチルウラシル誘導体およびその使用
CN119977961A (zh) 一种protac化合物及其制备方法和作为靶向tau的降解剂的应用
CN120289443A (zh) 一种白杨素和硫辛酸拼接物及其制备方法和应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160607

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191011

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210506

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211220

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210506

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I